EMA Unconvinced By Xiidra Dry Eye Data
Withdrawn Filing For Novartis’s Lifitegrast Was Found Wanting
The data package used to secure the US approval of Novartis's dry eye drug Xiidra (lifitegrast) was not enough to convince European regulators and experts in the field of eye diseases that the treatment should be sold in the EU.
